The definitive benchmark for antibiotic dealmaking
Antibiotic partnering is shaped by the growing challenge of antimicrobial resistance, with deal structures reflecting the unique scientific, regulatory, and commercial dynamics of developing anti-infective therapies.This report provides a comprehensive and structured analysis of 140+ antibiotic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
Establish a clear view of market standards
The report enables a precise understanding of how antibiotic deals are structured in practice, allowing you to:
- Benchmark comparable transactions with confidence
- Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
- Define realistic market parameters
- Clear insight into how deal terms vary by development stage, mechanism of action, and partner profile
- Support valuation and structuring decisions with evidence
- Ground internal discussions in real transaction data rather than assumptions
- Understand how leading companies approach dealmaking
- Visibility into partner behaviour and recurring deal structures across a scientifically critical and economically distinct therapeutic landscape
- Full visibility into deal structure and execution
This includes:
- Rights granted and retained
- Development and commercialization responsibilities
- Financial structures and payment triggers
- Key contractual provisions and protections
Designed for real-world BD and strategy use
The report is widely used to:
- Structure and benchmark anti-infective transactions
- Prepare for negotiations with well-defined market context
- Evaluate partnership opportunities and counterparties
- Support internal strategy with robust, defensible data
What’s included?
- 140+ antibiotic collaboration and licensing deals
- Financial terms, including upfronts, milestones, and royalties where disclosed
- Fully searchable deal directory (by company, mechanism, and development stage)
- Direct access to SEC-filed agreements and source documents
- Analysis of deal trends, key transactions, and active dealmakers
- A trusted, evidence-based reference for antibiotic dealmaking
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Antibiotic dealmaking by technology type
Chapter 2 - Trends in antibiotic dealmaking
Chapter 3 - Leading antibiotic deals
Chapter 4 - Most active antibiotic dealmakers
Chapter 5 - Antibiotic contracts dealmaking directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3B Pharmaceuticals
- Achaogen
- Acino Pharma
- Acurx Pharmaceuticals
- Advanz Pharma
- Allecra Therapeutics
- Allergan
- Almac Pharma Services
- Amerigen Pharmaceuticals
- Amicogen
- AMR
- Amyris
- Antibiotic Research UK
- Appili Therapeutics
- Arrevus
- Artizan Biosciences
- AstraZeneca
- Australian Research Council
- Avails Medical
- Basilea Pharmaceutica
- Biomedical Advanced Research and Development Authority
- Biophore Pharmaceuticals
- BioVersys
- Blacksmith Medicines
- Boston Pharmaceuticals
- Boston University
- Boulos and Cooper Pharmaceuticals
- Brii Biosciences
- Bugworks
- California Institute for Biomedical Research
- CARB-X
- Centre for Drug Research and Development (CDRD)
- Cepheid
- Checkpoint Therapeutics
- Chelexa Biosciences
- Cidara Therapeutics
- Citius Pharmaceuticals
- Cleveland Clinic
- Clinton Health Access Initiative
- Correvio Pharma
- Cosmo Pharmaceuticals
- Crestone Pharma
- CSPC Pharmaceutical Group
- Cumberland Pharmaceuticals
- Cystic Fibrosis Foundation
- Dana-Farber Cancer Institute
- Debiopharm
- Decibel Therapeutics
- Defense Threat Reduction Agency
- Deinove
- Department of Defense
- Department of Health and Human Services
- Dermin
- Dr. Reddy's Laboratories
- DSM Sinochem Pharmaceuticals
- Entasis Therapeutics
- Enterome Bioscience
- Eurofarma
- European Investment Bank
- Everest Medicines
- Evotec
- Federal Ministry of Education and Research (BMBF)
- Flightpath Biosciences
- Florida International University
- Forge Therapeutics
- Forsyth Institute
- Foundation for Innovative New Diagnostics
- Geom Therapeutics
- Global Antibiotic Research and Development Partnership
- GPCR Therapeutics
- GSK
- Hackensack Meridian Health
- Harvard Medical School
- Hasten Biopharmaceutic
- Helmholtz Centre for Infection Research
- Helperby Therapeutics
- Hikma Pharmaceuticals
- Hoffmann La Roche
- Hoth Therapeutics
- Hvidovre Hospital
- Ichor Biologics
- InfectoPharm
- Infex Therapeutics
- InfoRLife
- Ingenza
- Innosuisse
- Innovate UK
- Innoviva
- Innoviva Specialty Therapeutics
- Insmed Inc
- Italfarmaco
- Johns Hopkins University
- Journey Medical
- Kinnear Pharmaceuticals
- Knauer Scientific Instruments
- LegoChem Biosciences
- LEO Pharma
- Leukocare
- LifeArc
- Liverpool School of Tropical Medicine
- Luminarie
- Lysando
- Macrolide Pharma
- Magle Chemoswed
- Matinas Biopharma
- McMaster University
- MD Anderson Cancer Center
- Medicines Patent Pool Foundation
- Meitheal Pharmaceuticals
- Melinta Therapeutics
- Menarini
- Merck and Co
- Microbiotix
- MicuRx Pharmaceuticals
- Moleculin Biotech
- Monash University
- Nabriva Therapeutics
- Nanjing King-friend Biochemical Pharmaceutical
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
- National Institutes of Health
- Navamedic
- Next Gen Diagnostics
- Nosopharm
- Novartis
- Opal Therapeutics
- OpGen
- Oragenics
- Oricula Therpeutics
- Oxford Drug Design
- Paratek Pharmaceuticals
- Patheon
- Pfizer
- Phico Therapeutics
- Pieces Technologies
- Polyphor
- Prokaryotics
- Q-linea AB
- Qpex Biopharma
- QureTech Bio
- Recce Pharmaceuticals
- Recida Therapeutics
- RedHill Biopharma
- RMX Biopharma
- Roche
- Sandoz
- Saptalis Pharmaceuticals
- SeLux Diagnostics
- Shanghai Haini Pharmaceutical
- Shenzhen China Resources Gosun Pharmaceutical
- Shionogi
- Sinovant Sciences
- SpeeDx
- Spero Therapeutics
- Stoked Bio
- Strides Pharma Science
- Summit Therapeutics
- Suzhou NeuPharma
- Tabuk Pharmaceutical
- Taiba
- TaiGen Biotechnology
- TB Alliance
- Tetraphase Pharmaceuticals
- Teva Pharmaceutical Industries
- The Medicines Company
- Theravance Biopharma
- Thermo Fisher Scientific
- TLC BioSciences
- Trellis Bioscience
- University of Bergen
- University of California Los Angeles
- University of Florida
- University of Liverpool
- University of Melbourne
- University of New South Wales
- University of Queensland
- University of Technology Sydney
- University of Zurich
- US Army Medical Research Institute of Infectious Diseases
- UTILITY Therapeutics
- UT Southwestern Medical Center
- VenatoRx
- Verity Pharmaceuticals
- Vertex Pharmaceuticals
- Vinnova
- Warp Drive Bio
- Wellcome Trust
- Wuxi Apptec Laboratory Services
- X-Biotix Therapeutics
- X-chem
- Xellia Pharmaceuticals
- ZAI Laboratory
- Zoetis
- Zydus Cadila
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
